• Publications
  • Influence
International consensus report on the investigation and management of primary immune thrombocytopenia.
Previously published guidelines for the diagnosis and management of primary immune thrombocytopenia (ITP) require updating largely due to the introduction of new classes of therapeutic agents, and aExpand
  • 1,454
  • 119
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely dependent on clinical expertise and observations more than on evidence derived from clinical trials of high scientificExpand
  • 1,534
  • 81
The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
Because of its B‐cell depleting effect, rituximab has entered clinical trials in several autoimmune conditions. This study assesses the efficacy and safety of rituximab in 57 adults with chronicExpand
  • 299
  • 22
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) has not been determined.Expand
  • 536
  • 17
Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura.
PURPOSE To define response to therapy and ultimate outcome of adults with idiopathic thrombocytopenic purpura (ITP). PATIENTS AND METHODS We retrospectively analyzed patients with ITP diagnosedExpand
  • 322
  • 15
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review.
Whether the eradication of Helicobacter pylori infection can increase the platelet count in patients with immune thrombocytopenic purpura (ITP) is still a controversial issue. To provideExpand
  • 279
  • 11
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia.
The prevalence, clinical characteristics, and prognostic significance of immune thrombocytopenia (IT) in patients with chronic lymphocytic leukemia (CLL) have not been clearly determined. To clarifyExpand
  • 103
  • 11
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.
The effects of B-cell depletion with rituximab on regulatory T cells (Tregs) have not been determined. We investigated Tregs in patients receiving rituximab for chronic idiopathic thrombocytopenicExpand
  • 298
  • 10
How I treat thrombocytopenia in pregnancy.
A mild thrombocytopenia is relatively frequent during pregnancy and has generally no consequences for either the mother or the fetus. Although representing no threat in the majority of patients,Expand
  • 155
  • 10
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Idiopathic thrombocytopenic purpura (ITP) is characterized by a low platelet count, which is the result of both increased platelet destruction and insufficient platelet production. Although theExpand
  • 237
  • 9